Tuesday, Morgan Stanley revised its price target for ConvaTec Group Plc. (CTEC:LN) (OTC: CNVVY) shares, a global medical products and technologies company. The firm lowered the target to GBP2.83 from GBP2.97 while sustaining an Overweight rating on the stock.
The adjustment follows the company's first half of the year 2024 results, which have shaped analysts' expectations. Morgan Stanley's stance remains positive, citing ConvaTec's de-risked earnings and the appealing risk-reward profile for investors.
The analyst believes that the company's strategy for organic sales growth is largely unaltered and anticipates improving margins towards the mid-20s percentage range over the midterm.
ConvaTec's consensus earnings are considered largely de-risked following the results from the first half of 2024. Despite the near-term concerns due to low-cost competition (LCD) risk, the analyst suggests that this is already factored into the year-to-date stock performance. The belief is that ConvaTec's stock could experience a re-rating driven by several factors.
Firstly, the continued delivery of growth within the 5-6% midterm guidance range is expected to be a positive influence. Secondly, a recovery in the EBIT margin is anticipated, especially as foreign exchange and inflation pressures are predicted to reverse in the second half of the year. Lastly, the resolution of the LCD risk is seen as a potential clearing event that could further uplift the stock in the upcoming months.
In other recent news, ConvaTec Group Plc maintained its Buy rating from Berenberg, despite facing initial challenges in the first half of 2024. The medical products and technologies company's first-half results were marked by ongoing uncertainty and weaker-than-expected margins.
However, Berenberg's outlook for the company remains unchanged, emphasizing the importance of ConvaTec's reaffirmed revenue and margin guidance for the year 2024.
According to the Berenberg analyst, the first-half results did not reveal any new information that would influence their long-term perspective on the company.
This indicates that the firm believes ConvaTec's underlying value and potential are intact, regardless of the recent market reaction. In light of these recent developments, ConvaTec's commitment to its full-year 2024 guidance suggests the company's confidence in achieving its financial targets, despite the initial setbacks.
Berenberg's reiteration of the Buy rating implies that the recent market downturn does not reflect the company's fundamental strengths and future potential, as perceived by the analyst.
InvestingPro Insights
To complement Morgan Stanley's analysis, InvestingPro data provides additional context for ConvaTec Group's financial position. The company's net income is expected to grow this year, aligning with the analyst's positive outlook on the company's earnings potential. This growth expectation is further supported by the InvestingPro Tip that ConvaTec is trading at a low P/E ratio relative to its near-term earnings growth, suggesting potential undervaluation.
Another InvestingPro Tip indicates that ConvaTec's liquid assets exceed its short-term obligations, which could provide the financial flexibility needed to execute its organic growth strategy and margin improvement plans as highlighted by Morgan Stanley.
For investors seeking a more comprehensive analysis, InvestingPro offers 5 additional tips for ConvaTec Group, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.